Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 962-968

  Moisan, François ^a   Laroche Clary, Audrey ^a   Auzanneau, Céline ^a   Ricard, Nicolas ^a   Pourquier, Philippe ^a   Robert, Jacques ^a   Le morvan, Valérie ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; HISTONE H1; MESSENGER RNA; PACLITAXEL; SMALL INTERFERING RNA; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC POLYMORPHISM; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; NEOPLASM; PRIORITY JOURNAL; ULTRAVIOLET RADIATION;

EID: 84860486356     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs107     Document Type: Article

References (21)

1. Bardelli, A. et al. (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol., 28, 1254-1261.
2. Moasser, M.M. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene, 26, 6577-6592.
3. Di Leo, A. et al. (2008) Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur. J. Cancer, 44, 2791-2798.
4. Wagner, P. et al. (2005) Microtubule associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle, 4, 1149-1152.
5. Le Morvan, V. et al. (2006) Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-a'-vis the NCI-60 panel. Pharmacogenomics, 7, 843-852.
6. Wang, D. et al. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 4, 307-320.
7. Fisher, R.P. (2005) Secrets of a double agent: CDK7 in cell-cycle control and transcription. J. Cell Sci., 118, 5171-5180.
8. Donaldson, K.L. et al. (1994) Activation of p34cdc2 coincident with taxolinduced apoptosis. Cell Growth Differ., 10, 1041-1050.
9. Lehmann, A.R. (2003) DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie, 85, 1101-1111.
10. Wang, F. et al. (2008) DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol. Biomarkers Prev., 17, 507-517.
11. Lainé, J.P. et al. (2007) Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair, 6, 1264-1270.
12. Wolfe, K.J. et al. (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet. Genomics, 17, 897-905.
13. Xu, Z. et al. (2002) DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs, 13, 511-519.
14. Arienti, C. et al. (2011) Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy. J. Transl. Med., 9, 94.
15. Takayama, K. et al. (1995) Defects in the DNA repair and transcription gene ERCC2 in the cancer-prone disorder xeroderma pigmentosum group D. Cancer Res., 55, 5656-5663.
16. Chabalier, C. et al. (2006) BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle, 5, 1001-1007.
17. Ito, S. et al. (2007) XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol. Cell, 26, 231-243.
18. Cameroni, E. et al. (2010) On the traces of XPD: cell cycle matters- untangling the genotype-phenotype relationship of XPD mutations. Cell Div., 5, 24.
19. Chen, J. et al. (2003) Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature, 424, 228-232.
20. Li, X. et al. (2010) Drosophila Xpd regulates Cdk7 localization, mitotic kinase activity, spindle dynamics, and chromosome segregation. PLoS Genet., 6, e1000876.
21. Nackley, A.G. et al. (2006) Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science, 314, 1930-1933.